All In Biotech

Drug Trial Radar · NCT06402201

First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors

Phase 1, First-in-Human Study to Assess the Safety, Tolerability and Anti-tumor Activity of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

42

Planned (sponsor's estimate)

Start

May 24, 2024

Primary completion

Dec 30, 2026

Study completion Apr 5, 2027

Sponsor

Lead sponsor
CDR-Life AGIndustry
Sponsor type
Industry
First posted
May 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

CDR404 is a highly potent and specific T-cell engaging bispecific and bivalent antibody designed for the treatment of cancers positive for the tumor-associated antigen melanoma-associated antigen 4 (MAGE-A4). This is a first-in-human study designed to evaluate the safety, tolerability, and preliminary anti-tumor activity of CDR404 in adult patients who have the appropriate germline human leukocyte antigen HLA-A\*02:01 tissue marker and whose cancer is positive for MAGE-A4.

Conditions

  • Select Advanced Solid Tumors

Interventions

  • CDR404Biological

    IV infusions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Presence of dose limiting toxicities (DLTs)Time frame: From first dose to DLT period (21 days)
  2. Incidence and severity of (serious) adverse events ([S]AEs)Time frame: From first dose to 90 days after the last dose
  3. Anti-tumor response: Overall Response Rate (ORR)Time frame: From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months

Locations

18 sites in 6 countries. Site status is shown where the registry gives one.

  • Providence Cancer Institute

    Portland, Oregon

  • Pennsylvania Hospital

    Philadelphia, Pennsylvania

  • Universitair Ziekenhuis Antwerpen

    Antwerp, Belgium

  • Institut Jules Bordet

    Brussels, Belgium

  • Cliniques Universitaires Saint-Luc, UCL Ouvain

    Brussels, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • Rigshospitalet

    Copenhagen, Denmark

  • Istituto Clinico Humanitas

    Milan, Italy

  • Isituto Europeo di Oncologia (IEO)

    Milan, Italy

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Institut Catala d'Oncologia, L'Hospitalet de Llobregat (ICO)

    Barcelona, Spain

  • Hospital 12 de Octubre

    Madrid, Spain

  • START Madrid

    Madrid, Spain

  • Hospital Universitari i Politecnic La Fe

    Valencia, Spain

  • Instituto de Investigacion Sanitaria (INCLIVA)

    Valencia, Spain

  • The Beatson West of Scotland Cancer Center

    Glasgow, United Kingdom

  • Guys and St Thomas' NHS Foundation Trust

    London, United Kingdom

  • Royal Marsden Hospital

    Sutton, London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.